Prior authorization in the treatment of patients with pDPN and FM

Pain Practice

Volumn 15, Issue 1, 2015, Pages E9-E19

  Placzek, Hilary E D ^a   Masters, Elizabeth T ^b   Gu, Tao ^a   Cappelleri, Joseph C ^b   Wasser, Thomas E ^a   Clair, Andrew G ^b   Cook, Joseph P ^b   Eisenberg, Debra F ^a  

^a HEALTHCORE INC   (United States)

^b PFIZER INC   (United States)

Author keywords

Diabetic neuropathy; Fibromyalgia; Healthcare utilization; Pain; Pharmacologic treatment; Prior authorization

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; DULOXETINE; MILNACIPRAN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PREGABALIN; TRICYCLIC ANTIDEPRESSANT AGENT; ANALGESIC AGENT; CYCLOPROPANE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CHIROPRACTIC; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DEPRESSION; FEMALE; FIBROMYALGIA; FOLLOW UP; HEALTH CARE CONCEPTS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INSURANCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PAINFUL DIABETIC PERIPHERAL NEUROPATHY; PERIPHERAL NEUROPATHY; PHARMACY; PHYSIOTHERAPY; PRIOR AUTHORIZATION; RETROSPECTIVE STUDY; SLEEP DISORDER; TRANSCUTANEOUS NERVE STIMULATION; AGED; COST OF ILLNESS; DIABETIC NEUROPATHIES; ECONOMICS; HEALTH INSURANCE; HEALTH SERVICE; MIDDLE AGED; UTILIZATION;

ADULT; AGED; ANALGESICS; COHORT STUDIES; COST OF ILLNESS; CYCLOPROPANES; DIABETIC NEUROPATHIES; DULOXETINE HYDROCHLORIDE; FEMALE; FIBROMYALGIA; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; INSURANCE CLAIM REVIEW; INSURANCE, HEALTH; INSURANCE, PHARMACEUTICAL SERVICES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREGABALIN; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS;

EID: 84921826851     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/papr.12258     Document Type: Article

References (34)

1. International Association for the Study of Pain [homepage on the Internet]. IASP Taxonomy. Washington: International Association for the Study of Pain; 2011 [updated 2012 May 22]. Available from: http://www.iasp-pain.org/Content/NavigationMenu/GeneralResourceLinks/PainDefinitions/default.htm.
2. Davies M, Williams R, Brophy S, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29:1518-1522.
3. Snedecor S, Sudharshan L, Cappelleri JC, Sadosky A, Mehta S, Botteman M. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract. 2014;14:167-184.
4. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum. 1990;33:160-172.
5. Lawrence R, Felson D, Helmick C, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Arthritis Rheum. 2008;58:26-35.
6. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62:600-610.
7. Gilman BH, Kautter J. Impact of multi-tiered copayments on the use and cost of prescription drugs among Medicare beneficiaries. Health Serv Res. 2008;43:478-495.
8. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription drug utilization and spending. N Engl J Med. 2003;349:2224-2232.
9. Huskamp HA, Frank RG, McGuigan KA, Zhang Y. The impact of a three-tier formulary on demand response for prescription drugs. J Econ Manag Strategy. 2005;14:729-753.
10. Roblin DW, Platt R, Goodman MJ, et al. Effect of increased cost sharing on oral hypoglycemic use in five managed care organizations: how much is too much? Med Care. 2005;43:951-959.
11. Gleason PP, Gunderson BW, Gericke KR. Are incentive-based formularies inversely associated with drug utilization in managed care? Ann Pharmacother. 2005;39:339-345.
12. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically Ill. JAMA. 2004;291:2344-2350.
13. Kamal-Bahl S, Briesacher B. How do incentive-based formularies influence drug selection and spending for hypertension? Health Aff. 2004;23:227-236.
14. Rector TS, Finch MD, Danzon PM, Pauly MV, Manda BS. Effect of tiered prescription copayment on the use of preferred brand medications. Med Care. 2003;41:398-406.
15. Thomas CP, Wallack SS, Lee S, Ritter GA. Impact of health plan design and management on retirees' prescription drug use and spending, 2001. Health Aff. [suppl web exclusives]. 2002; doi: 10.1377/hlthaff.w2.408. Available from: http://content.healthaffairs.org/content/early/2002/12/04/hlthaff.w2.408.long.
16. Margolis JM, Cao Z, Onukwugha E, et al. Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans. Am J Manag Care. 2010;16:447-456.
17. Margolis JM, Johnston SS, Chu BC, et al. Effects of a Medicaid prior authorization policy for pregabalin. Am J Manag Care. 2009;15:e95-e102.
18. Peterson JL, Barron JJ, Hammill BG, et al. Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the healthcore integrated research database. Am Heart J. 2010;159:462-470.
19. Rosenbaum P, Rubin D. The central role of propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
20. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-2281.
21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
22. Rosner B. Fundamentals of Biostatistics, 7th ed. Boston, MA: Brooks/Cole, 2011.
23. Udall M, Louder A, Suehs BT, Cappelleri JC, Joshi AV, Patel NC. Impact of a step-therapy protocol for pregabalin on healthcare utilization and expenditures in a commercial population. J Med Econ. 2013;16:784-792.
24. Suehs BT, Louder A, Udall M, Cappelleri JC, Joshi AV, Patel NC. Impact of a pregabalin step therapy policy among medicare advantage beneficiaries. Pain Pract. 2014;14:419-426.
25. Jacobson VJ, Christofferson S, Humble CG, Wegner SE, Feaganes JR, Trygstad TK. Pharmacist and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program. J Manage Care Pharm. 2010;16:250-263.
26. Raper JL, Willig JH, Lin HY, et al. Uncompensated medical provider costs associated with prior authorization for prescription medications in an HIV clinic. Clin Infect Dis. 2010;51:718-724.
27. Epling JW, Mader EMM, Morley CP. Practice characteristics and prior authorization costs: secondary analysis of data collected by SALT-Net in 9 Central New York primary care practices. BMC Health Serv Res. 2014;14:109-115.
28. Johnston SS, Udall M, Alvir J, et al. Association between Pregabalin Access Restrictions and Pain-Related Healthcare Expenditures in Medicare Supplemental Health Plans. Poster presented at The Academy of Managed Care Pharmacy 2012 Educational Conference, October 3-5, 2012, Cincinnati, Ohio.
29. Vo T, Rice ASC, Dworkin RH. Non-steroidal anti-inflammatory drugs for neuropathic pain: how do we explain continued widespread use? Pain. 2009;143:169-171.
30. Painter JT, Crofford LJ. Chronic opioid use in fibromyalgia syndrome: a clinical review. J Clin Rheumatol. 2013;19:72-77.
31. Buckhardt CS, Goldenberg D, Crofford L, et al. Guideline for the Management of Fibromyalgia Syndrome Pain in Adults and Children. Glenview, IL: American Pain Society; 2005.
32. Carville SF, Arendt-Nielson S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008;67:536-541.
33. Johnston SS, Sadosky A, Cappelleri JC, Johnson BH, Shrady G, Silverman SL. Pregabalin Prior Authorization and Medication Interactions. Poster presented at the American Academy of Pain Management, September 26-29, 2013, Orlando, Florida.
34. Madigan D, Ryan PB, Schuemie M, et al. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol. 2013;178:645-651.